Dive Brief: The Food and Drug Administration has granted a full approval to Gilead’s COVID-19 drug Veklury, making it the first medicine to win a standard clearance from the agency to treat the disease caused by the new coronavirus. The FDA authorized Veklury for emergency use in May, a declaration that’s only valid during a… Read More »
When its U.S. patent cliff for HIV med Truvada was still on the horizon, Gilead Sciences won approval for follow-up med Descovy and launched an aggressive campaign to switch patients to the new drug. Now, that cliff is here, and Gilead will have to see if all its hard work has paid off. Israeli drugmaker Teva… Read More »
Amid daily headlines about COVID-19 vaccines and trends, Gilead’s Veklury, also known as remdesivir, remains the only antiviral drug authorized to treat the illness. With a new move from the FDA, the medicine’s emergency green light is a little broader—despite some lingering questions about its efficacy. Under the expanded emergency use authorization (EUA), all hospitalized… Read More »
UnitedHealthcare has a history of limiting HIV drug costs, including offering cash incentives to patients who opt for low-priced regimens. Now, in a potentially major blow to HIV giant Gilead Sciences, the insurer has set its eyes on one of the California drugmaker’s new therapies. Gilead’s new HIV PrEP option, Descovy, will no longer be covered… Read More »
In quick succession, Gilead Sciences has not only lost an early attempt to overturn a massive CAR-T patent infringement verdict, but now a judge has also ordered hundreds of millions of enhanced damages for plaintiff Bristol Myers Squibb. Judge Philip Gutierrez in California expanded the total verdict to $ 1.2 billion from a prior… Read More »